Avenet P, Léonardon J, Besnard F, Graham D, Frost J, Depoortere H, Langer S Z, Scatton B
Synthélabo Recherche, CNS Research Department, Bagneux, France.
Eur J Pharmacol. 1996 Jan 25;296(2):209-13. doi: 10.1016/0014-2999(95)00700-8.
The NMDA receptor antagonist ifenprodil contains two asymmetric centres which give rise to four stereoisomeric forms of this molecule. The inhibitory effects of each of these stereoisomers on recombinant NMDA receptors expressed from NR1A/NR2A and NR1A/NR2B subunit combinations were studied in Xenopus oocytes by voltage-clamp recording. All four ifenprodil stereoisomers were potent antagonists at NR1A/NR2B (IC50 < 0.8 microM), but weak antagonists at NR1A/NR2A receptors (IC50 > 100 microM). In heteromeric NR1A/NR2B receptors, (+) erythro- and (-) threo-ifenprodil (IC50 0.21 and 0.22 microM, respectively) were about 4 times more potent than (-) erythro- and (+) threo-ifenprodil (IC50 0.81 and 0.76, respectively). These results show that the stereoisomers of ifenprodil exhibit a weak though significant stereoselectivity at the NR1A/NR2B NMDA receptor subtype.
N-甲基-D-天冬氨酸(NMDA)受体拮抗剂艾芬地尔含有两个不对称中心,由此产生该分子的四种立体异构形式。通过电压钳记录法,在非洲爪蟾卵母细胞中研究了这些立体异构体对由NR1A/NR2A和NR1A/NR2B亚基组合表达的重组NMDA受体的抑制作用。所有四种艾芬地尔立体异构体在NR1A/NR2B受体上均为强效拮抗剂(半数抑制浓度[IC50]<0.8微摩尔/升),但在NR1A/NR2A受体上为弱拮抗剂(IC50>100微摩尔/升)。在异聚体NR1A/NR2B受体中,(+)赤型-和(-)苏型-艾芬地尔(IC50分别为0.21和0.22微摩尔/升)的效力比(-)赤型-和(+)苏型-艾芬地尔(IC50分别为0.81和0.76)约强4倍。这些结果表明,艾芬地尔的立体异构体在NR1A/NR2B NMDA受体亚型上表现出较弱但显著的立体选择性。